Cobicistat (Tybost) discontinuation in UK by the end of 2026

29 January 2026. Related: Early access, Treatment alerts, Treatment access.

Simon Collins, HIV i-Base

In January 2026, Gilead Sciences announced that cobicistat, a pharmacokinetic booster marketed as Tybost, will be withdrawn from the UK market at the end of the year.

This decision is being made for commercial decisions, die to significantly reduced global use of cobicistat as a single drug.

Fixed dose combinations that include cobicistat will continue to be available.

The last date for prescriptions in the UK will be 18 December 2026, with shelf life running until December 2028.

For further information please contact Gilead Medical Information:
email: ukmed.info@gilead.com
Or call: 0800 0113 700